Retinal Vein Occlusion - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 78 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Retinal Vein Occlusion - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Retinal Vein Occlusion - Pipeline Review, H2 2014', provides an overview of the Retinal Vein Occlusion's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Retinal Vein Occlusion and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Retinal Vein Occlusion products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Retinal Vein Occlusion pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Retinal Vein Occlusion
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Retinal Vein Occlusion pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Retinal Vein Occlusion Overview 7
Therapeutics Development 8
Pipeline Products for Retinal Vein Occlusion - Overview 8
Pipeline Products for Retinal Vein Occlusion - Comparative Analysis 9
Retinal Vein Occlusion - Therapeutics under Development by Companies 10
Retinal Vein Occlusion - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Retinal Vein Occlusion - Products under Development by Companies 14
Retinal Vein Occlusion - Companies Involved in Therapeutics Development 15
F. Hoffmann-La Roche Ltd. 15
Allergan, Inc. 16
pSivida Corp. 17
NicOx S.A. 18
ThromboGenics NV 19
Ohr Pharmaceutical Inc. 20
Kala Pharmaceuticals, Inc. 21
Mabion SA 22
Retinal Vein Occlusion - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
fluocinolone acetonide - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
squalamine lactate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
beclomethasone dipropionate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
loteprednol etabonate - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ranibizumab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ocriplasmin (recombinant) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NCX-434 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NCX-422 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
AVA-101 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ranibizumab biosimilar - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Retinal Vein Occlusion - Recent Pipeline Updates 49
Retinal Vein Occlusion - Discontinued Products 65
Retinal Vein Occlusion - Product Development Milestones 66
Featured News & Press Releases 66
Jul 31, 2014: Kala Pharmaceuticals Initiates Phase 2 Clinical Trial to Evaluate LE-MPP (KPI-121) in Patients with Retinal Vein Occlusion and Diabetic Macular Edema 66
Sep 27, 2013: New data for Novartis drug Lucentis reinforces transformational efficacy and well-established safety profile across four indications 67
Aug 20, 2013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion 68
May 08, 2013: Novartis Reports New Data On Lucentis At Association For Research In Vision And Ophthalmology Annual Meeting 69
Sep 05, 2012: New Data For Novartis Drug Lucentis Confirms Long-term Efficacy And Safety Profile And Benefits Of Individualized Treatment 70
Feb 20, 2012: Bayer Announces Positive One Year Results From Phase III Study In Central Retinal Vein Occlusion Of VEGF Trap-Eye 71
Feb 14, 2012: Gene Signal And Collaborators Demonstrate Successful Activity Of Topical Aganirsen In Models Of Retinal Neovascular Disease 73
Jan 13, 2012: Genentech Announces First Milestone Payment To ForSight VISION4 For Development Of Sustained Delivery Of Lucentis 74
Aug 18, 2011: Health Canada Approves Lucentis To Treat Vision Loss Resulting From Retinal Vein Occlusion 75
Aug 17, 2011: Regeneron To Present Data From EYLEA Clinical Studies At ASRS 2011 Annual Meeting 75
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78

List of Tables
Number of Products under Development for Retinal Vein Occlusion, H2 2014 8
Number of Products under Development for Retinal Vein Occlusion - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Retinal Vein Occlusion - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 15
Retinal Vein Occlusion - Pipeline by Allergan, Inc., H2 2014 16
Retinal Vein Occlusion - Pipeline by pSivida Corp., H2 2014 17
Retinal Vein Occlusion - Pipeline by NicOx S.A., H2 2014 18
Retinal Vein Occlusion - Pipeline by ThromboGenics NV, H2 2014 19
Retinal Vein Occlusion - Pipeline by Ohr Pharmaceutical Inc., H2 2014 20
Retinal Vein Occlusion - Pipeline by Kala Pharmaceuticals, Inc., H2 2014 21
Retinal Vein Occlusion - Pipeline by Mabion SA, H2 2014 22
Assessment by Monotherapy Products, H2 2014 23
Number of Products by Stage and Target, H2 2014 25
Number of Products by Stage and Mechanism of Action, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Retinal Vein Occlusion Therapeutics - Recent Pipeline Updates, H2 2014 49
Retinal Vein Occlusion - Discontinued Products, H2 2014 65